The estimated Net Worth of James P Patton is at least $102 Thousand dollars as of 24 October 2013. James Patton owns over 25,000 units of Ayala Pharmaceuticals stock worth over $1,758 and over the last 21 years he sold ADXS stock worth over $0. In addition, he makes $100,402 as Independent Non-Executive Vice Chairman of the Board at Ayala Pharmaceuticals.
James has made over 1 trades of the Ayala Pharmaceuticals stock since 2013, according to the Form 4 filled with the SEC. Most recently he bought 25,000 units of ADXS stock worth $100,000 on 24 October 2013.
The largest trade he's ever made was buying 25,000 units of Ayala Pharmaceuticals stock on 24 October 2013 worth over $100,000. On average, James trades about 1,250 units every 0 days since 2004. As of 24 October 2013 he still owns at least 87,909 units of Ayala Pharmaceuticals stock.
You can see the complete history of James Patton stock trades at the bottom of the page.
Dr. James P. Patton M.D. serves as Independent Non-Executive Vice Chairman of the Board of the Company. Dr. Patton was the Chairman of our Board of Directors from November 2004 until December 2005, as well as a period from July 2013 until May 2015, and was our Chief Executive Officer from February 2002 to November 2002. Since February 1999, Dr. Patton has been the Vice President of Millennium Oncology Management, Inc., which is a consulting company in the field of oncology services delivery. Dr. Patton was a trustee of Dundee Wealth US, a mutual fund family, from October 2006 through S ptember 2014. He is a founder and has been chairman of VAL Health, LLC, a health care consultancy, from 2011 to the present. In addition, he was President of Comprehensive Oncology Care, LLC, a company that owned and operated a cancer treatment facility in Exton, Pennsylvania from 1999 until its sale in 2008. From February 1999 to September 2003, Dr. Patton also served as a consultant to LibertyView Equity Partners SBIC, LP, a venture capital fund based in Jersey City, New Jersey. From July 2000 to December 2002, Dr. Patton served as a director of Pinpoint Data Corp. From February 2000 to November 2000, Dr. Patton served as a director of Healthware Solutions. From June 2000 to June 2003, Dr. Patton served as a director of LifeStar Response. He earned his B.S. from the University of Michigan, his Medical Doctorate from Medical College of Pennsylvania, and his M.B.A. from Penn’s Wharton School. Dr. Patton was also a Robert Wood Johnson Foundation Clinical Scholar. He has published papers regarding scientific research in human genetics, diagnostic test performance and medical economic analysis. Dr. Patton’s experience as a trustee and consultant to funds that invest in life science companies provide him with the perspective from which we benefit. Additionally, Dr. Patton’s medical experience and service as a principal and director of other life science companies make.
As the Independent Non-Executive Vice Chairman of the Board of Ayala Pharmaceuticals, the total compensation of James Patton at Ayala Pharmaceuticals is $100,402. There are 6 executives at Ayala Pharmaceuticals getting paid more, with Kenneth A. Berlin J.D. having the highest compensation of $1,162,449.
James Patton is 62, he's been the Independent Non-Executive Vice Chairman of the Board of Ayala Pharmaceuticals since 2015. There are 1 older and 8 younger executives at Ayala Pharmaceuticals. The oldest executive at Ayala Pharmaceuticals Inc. is Richard Berman, 77, who is the Independent Director.
James's mailing address filed with the SEC is 305 COLLEGE ROAD EAST, , PRINCETON,, NJ, 08540.
Over the last 21 years, insiders at Ayala Pharmaceuticals have traded over $12,060,930 worth of Ayala Pharmaceuticals stock and bought 7,108,817 units worth $19,940,745 . The most active insiders traders include Biotech Fund I, L.P.Israel ..., Capital Partners Gp, L.L.C...., and Thomas A Moore. On average, Ayala Pharmaceuticals executives and independent directors trade stock every 107 days with the average trade being worth of $12,473. The most recent stock trade was executed by Biotech Fund I, L.P.Israel ... on 7 February 2024, trading 27,847,159 units of ADXS stock currently worth $11,138,864.
advaxis (nasdaq: adxs) is a late -stage biotechnology company developing multiple cancer immunotherapies based on its proprietary platform that redirects the immune system to kill cancer. the advaxis technology, using bioengineered live attenuated bacteria, listeria monocytogenes (lm), actively suppresses key components in the tumor microenvironment that contribute to the tumors growth and protection from immunologic attack.
Ayala Pharmaceuticals executives and other stock owners filed with the SEC include: